Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Currently Reading
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

Surabhi Dangi-Garimella, PhD
A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.
A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies. The study results were presented during a poster session at the 2017 Annual Meeting of the American Society of Clinical Oncology.

Filgrastim EP2006 (Zarxio) was the first biosimilar approved by the FDA for commercial use in the United States in 2016. The current phase 3 study compared the impact of switching the reference product with the biosimilar and also the biosimilar with the reference product, in the said patient population.

The 218 German patients receiving 5 µg/kg/day filgrastim over 6 chemotherapy cycles were randomized equally into 4 arms: 2 arms received only 1 product, either the biosimilar or reference (unswitched), and 2 arms (switched) received alternating treatments every other cycle (the first then reference or vice versa, over cycles 1 to 6). Four patients did not receive treatment: 2 in the reference group, 1 in the switched group, and 1 in the biosimilar group.

A total of 107 patients switched treatment, and 51 patients received reference drug in all cycles. Incidence of febrile neutropenia (FN) was 3.4% (switched) vs 0% (reference) (95% CI, -9.65 to 4.96). Infections occurred in 9.3% of the switched cohort, compared with 9.9% in the reference cohort. Hospitalization due to FN was low with 1 patient in cycle 6 (switched).

Treatment-related adverse event (TEAE) related to filgrastim were reported in 42.1% (switched) vs 39.2% (reference) (all cycles). The most frequent TEAE was musculoskeletal/connective tissue disorders related to filgrastim, which occurred in 35.5% (switched) compared with 39.2% (reference) (all cycles). These events included bone pain (30.8% vs 33.3%).

No neutralizing or clinically relevant antibodies against recombinant human granulocyte-colony stimulating factor were detected post-dose while switching from reference product to biosimilar and vice versa.

The authors concluded that there was no evidence of clinically meaningful differences related to efficacy, safety, or immunogenicity when patients with breast cancer were switched from reference to biosimilar filgrastim, or from biosimilar to reference filgrastim.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!